We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 470

Maintaining the Attorney-Client Privilege Even with a Third-Party Presence
  • Kaye Scholer LLP
  • USA
  • February 2 2016

The modern business landscape is replete with examples of privileged legal communications occurring outside traditional corporate silos. For years


ILPA Releases New Private Equity Fee Reporting Guidelines; Presses for Additional Fund Transparency
  • Kaye Scholer LLP
  • USA
  • February 1 2016

On January 29, 2016, the Institutional Limited Partners Association (ILPA) released the ILPA Fee Reporting Template (version 1.0) (the Template


Taking a Science Expert Deposition to Set Up a Daubert Motion
  • Kaye Scholer LLP
  • USA
  • January 27 2016

In any deposition, counsel wants to get the jury-friendly admission from a Plaintiff’s medical expert that will be the key to a defense


Excluding or Limiting FDA Regulatory Expert Opinion
  • Kaye Scholer LLP
  • USA
  • January 27 2016

It has become increasingly commonplace in pharmaceutical or medical device product liability litigationparticularly large, centralized mass tort


Excluding Expert Opinion Impugning Corporate Ethics, Motive and State of Mind
  • Kaye Scholer LLP
  • USA
  • January 27 2016

In product liability litigations there has been an increasing trend for plaintiffs to hire “‘expert’ witnesses whose intended role is more to argue


Mastery in the MDL: Maximizing the MDL Daubert Process
  • Kaye Scholer LLP
  • USA
  • January 27 2016

Imagine having the ability to defeat dozens, if not hundreds or even thousands of cases, with a single motion. From a Defendant’s perspective


Deconstructing Plaintiffs’ Peer-Reviewed Scientific Literature
  • Kaye Scholer LLP
  • USA
  • January 27 2016

Although peer-reviewed scientific evidence is central to most mass tort and product liability litigations, peer review is not foolproof and the fact


And Now a Word from the Panel: 2015 JPML Practice Trends
  • Kaye Scholer LLP
  • USA
  • January 27 2016

Welcome to our fourth year of “And Now a Word from the Panel,” a bimonthly column that “rides the circuit” with the Judicial Panel on Multidistrict


Corporate and Antitrust Alert: FTC Raises Hart-Scott-Rodino Premerger Filing Thresholds
  • Kaye Scholer LLP
  • USA
  • January 22 2016

The Federal Trade Commission (FTC) announced its annual revision of the filing thresholds under the Hart-Scott-Rodino Antitrust Improvements Act (HSR


Significant 2015 Decisions Affecting Private M&A
  • Kaye Scholer LLP
  • USA
  • January 15 2016

This decision serves as a reminder to companies engaging in equity financings that they should consider the risk of investors undertaking a hostile